Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07090733
Recruiting Not applicable

Ultrasound Guided Interscalene, Suprascapular and Anterior Glenoid Nerve Blocks on Diaphragmatic Excursion and Analgesia Following Arthroscopic Shoulder Surgery

NCT07090733 · tracked via the Priya Life Science Egypt tracker
Sponsor
Tanta University
Phase
Not applicable
Started
2025-01-01
Last updated
2025-07-29

Condition(s) studied

Interscalene BlockSuprascapular Nerve BlockAnterior Glenoid Nerve BlockDiaphragmatic ExcursionAnalgesiaArthroscopic Shoulder Surgery

Investigational drug(s) / intervention(s)

Interscalene brachial plexus blockSuprascapular nerve blockAnterior glenoid blockSuprascapular nerve block + Anterior glenoid block

Interscalene brachial plexus block: Patients will receive general anesthesia, plus an ultrasound-guided interscalene brachial plexus block (ISB) with the injection of 15 mL of 0.25% bupivacaine.

Suprascapular nerve block: Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB) with injection of 15 ml of 0.25% bupivacaine.

Anterior glenoid block: Patients will receive general anesthesia plus an ultrasound-guided anterior glenoid block with injection of 15 ml of 0.25% bupivacaine.

Suprascapular nerve block + Anterior glenoid block: Patients will receive general anesthesia, along with a total volume of 30 mL of 0.25% bupivacaine, divided into 15 mL for ultrasound-guided SSNB and 15 mL for ultrasound-guided anterior glenoid block.

Study summary

This study aims to evaluate the diaphragmatic movement and postoperative analgesia following anterior glenoid, suprascapular, and interscalene nerve blocks in patients undergoing elective arthroscopic shoulder surgery.

Eligibility

Sex
ALL
Min age
21 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 21 to 65 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status I or II. * Scheduled for arthroscopic shoulder surgery. Exclusion Criteria: * Patient's refusal to participate. * Patients with a history of allergy to local anesthetics. * Patients with a history of chronic use of painkillers. * Patients presented with mental dysfunction. * Patients with coagulation disorders. * Patients presented with skin or soft tissue infection at the proposed site of needle Insertion. * Pregnant Patients. * Patients with Chronic Obstructive Pulmonary Disease (COPD) or a Body Mass Index (BMI) of more than 40.

Primary outcome measure(s)

  • Incidence of hemi-diaphragmatic paralysis — 24 hours postoperatively
    Incidence of hemi-diaphragmatic paralysis determined by ultrasound-guided assessment of diaphragmatic excursion. Diaphragmatic excursion will be measured before procedure (pre-block), 30 minutes after performing the block and post operative after complete recovery in post-anesthesia care unit (PACU).

Trial sites (1)

FacilityCityRegionStatus
Tanta University Tanta El-Gharbia Recruiting

More Tanta University trials in Egypt

Carotid Ultrasound for Post-Spinal Anesthesia Hypotension in Elderly Hip Surgery Starting soon
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients Recruiting
Pelvic Floor Therapies for Lifelong Premature Ejaculation Recruiting
Carotid Artery Corrected Flow Time and Inferior Vena Cava Collapsibility Index for Prediction of Hypotension After Induction of General Anesthesia in Geriatric Patients Undergoing Elective Surgery Recruiting
Laparoscopic Management of Gastroesophageal Reflux Disease in Children Recruiting

Other trials for the same condition

Combined Intrathecal Dexmedetomidine and Adductor Canal Block for Analgesia After Total Knee Arthroplasty Recruiting
Maxillary and Mandibular Nerve Block Recruiting
Efficacy of Dexmedetomidine VS Magnesium Sulphate With Bupivacaine in Erector Spinae Block for Thoracotomy Pain Recruiting
Analgesic Effect of Bupivacaine Plus Ketamine Versus Bupivacaine Alone in Transversalis Fascia Plane Block Starting soon
Analgesic Efficacy of Blocking Nerve to Vastus Lateralis Muscle Versus Lateral Femoral Cutaneous Nerve After Knee Surgeries Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07090733 on ClinicalTrials.gov ↗ ← All trials in Egypt